Abstract
Background and objective: Hematoma expansion (HE) is a major determinant of neurological deterioration and poor outcome in intracerebral hemorrhage (ICH) and represents an appealing therapeutic target. We analyzed the prognostic effect of different degrees of HE.
Methods: retrospective analysis of ICH patients admitted at eight academic institutions in Italy, Germany, Canada, China and United States. All patients underwent baseline and follow-up imaging for HE assessment. Relative HE (rHE) was classified as follows: (none < 0%), mild (0-33%), moderate (33.1-66%) and severe (> 66%). Absolute HE (aHE) was classified as none (< 0 mL), mild (0-6.0 mL), moderate (6.1-12.5 mL) and severe (> 12.5 mL). Predictors of poor functional outcome (90 days modified Rankin Scale 4-6) were explored with logistic regression.
Results: We included 2163 subjects, of whom 1211 (56.7%) had poor outcome. The occurrence of severe aHE or rHE was more common in patients with unfavorable outcome (13.9% vs 6.5%, p<0.001 and 18.3% vs 7.2 %, p<0.001 respectively). This association was confirmed in logistic regression (rHE OR 1.98, 95% CI 1.38-2.82, p<0.001; aHE odds ratio (OR)1.73,95% confidence interval (CI) 1.23-2.45, p=0.002) while there was no association between mild or moderate HE and poor outcome. The association between severe HE and poor outcome was significant only in patients with baseline ICH volume below 30 mL.
Discussion: The strongest association between HE and outcome was observed in patients with smaller initial volume experiencing severe HE. These findings may inform clinical trial design and guide clinicians in selecting patients for anti-expansion therapies.
==========
- Received December 20, 2022.
- Accepted in final form June 14, 2023.
- © 2023 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
